Marie Celeste Simon

This study shows that reducing hepatic ASS1 protects against obesity and liver disease by enhancing brown fat thermogenesis.

This study shows MYC suppresses mitochondrial function in HCC by promoting mitophagy via NRF1, and inhibiting this pathway reduces tumor growth.

This study shows HIF2α prevents GLS1 clustering in mitochondria, protecting ccRCC cells from glutamine deprivation, and suggests targeting GLS1 clustering could enhance HIF2 therapy.

This study identifies GGPP, a mevalonate pathway byproduct, as critical for chemoresistance in TP53mut AML through ROS regulation and mitochondria stress response, suggesting statin-based therapies could be effective.

The paper shows BMAL1-HIF2α heterodimers contribute to ccRCC growth and drug sensitivity by regulating HIF2 target genes and chromatin association.

The paper shows that glutamine availability affects the number of type 1 conventional dendritic cells (cDC1s) in tumor microenvironments, which impacts anti-tumor immune responses.

This paper identifies increased ZFPM2 dosage as a mechanism for 46,XX testicular development independent of SRY in a mosaic individual.

The paper develops a method to quantify gene expression memory and identify regulators of cell state transitions, showing that modulating PI3K and TGF-β pathways can reduce drug resistance in melanoma.

The paper identifies FBP1 as a nonenzymatic regulator that inhibits AKT activation to prevent insulin hyperresponsiveness and associated liver pathologies.

The paper shows DNA methylation prevents HIF binding, affecting hypoxia responses and tumour immunotolerance.